Trial reportAmerican journal of preventive medicine2025
A Pilot RCT Exploring Heated Tobacco Product Substitution for Menthol Cigarettes.
Trial report in American journal of preventive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05499377 (Effects of Heated Tobacco Product Flavor on Tobacco Use Behavior and Abuse Liability Among Menthol Cigarette Smokers), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Heated Tobacco Product Flavor on Tobacco Use Behavior and Abuse Liability Among Menthol Cigarette Smokers
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionFlavors are a key regulatory target for tobacco products, but little is known about how flavors influence the appeal of heated tobacco products, such as IQOS, for people who smoke. This study assessed differences in the substitution feasibility of menthol- and regular/tobacco-flavored IQOS for menthol cigarettes. STUDY
designThis was an unblinded 2-week, parallel-group randomized pilot clinical trial. SETTING/
participantsThirty adults who smoked menthol cigarettes in Richmond, VA completed clinical laboratory sessions (Monday and Friday) and reported at-home tobacco consumption. Data were collected from November 2022 to September 2023 and analyzed from October 2023 to February 2024.
interventionParticipants were randomized to use IQOS 2.4 with fresh menthol (IQOS-M) or regular tobacco (IQOS-T) HeatSticks (1:1) during Week 2 of the study in the clinical laboratory and throughout the second week while they were at home.
main outcome measuresLaboratory visits involved 10-puff directed use bouts with puff topography, plasma nicotine measurement, subjective effects questionnaires, and the Experimental Tobacco Marketplace task. The primary outcome was the cross-price elasticity of IQOS in the Experimental Tobacco Marketplace at the final clinical laboratory session. Electronic daily diaries measured tobacco consumption at home.
resultsIn the Experimental Tobacco Marketplace, the average (SD) cross-price elasticity for IQOS was 0.67 (0.09) when IQOS-M and IQOS-T were available concurrently versus 0.14 (0.03) when only IQOS-T was available (p<0.05). At home, participants reduced their typical cigarette consumption by 80% when they had access to IQOS-M versus 37% with IQOS-T (p<0.05). Differences in puff topography and nicotine delivery across IQOS flavors were not significant (p>0.05).
conclusionsAccess to menthol-flavored heated tobacco products is an important determinant of potential substitution for people who smoke menthol cigarettes but may not be sufficient to promote complete substitution. Tobacco regulatory policies that restrict access to menthol-flavored heated tobacco products could promote complete tobacco cessation but may reduce attempts to substitute with heated tobacco products among people who smoke menthol cigarettes.
trial registrationThis trial was preregistered at www. CLINICALTRIALS: gov (NCT05499377).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.